Retina

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

The company has secured $170 million (approximately €157 million) in Series B funding

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema

The drug is a biosimilar for aflibercept 2 mg (Eylea)

Apellis will seek re-examination from the CHMP following the opinion

A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2

The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research

The diagnostic and monitoring tools use artificial intelligence-based models.

The multi-institutional found that a genetic variation common in people of African ancestry is linked with an increased risk of complications from diabetes, including diabetic retinopathy, which has previously been linked to genetic variations called single nucleotide polymorphisms, or SNPs, but these associations have been studied primarily in individuals of European and Asian ancestry.

The results were presented at a symposium during the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, and mark the first large-scale trial specifically designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy.

Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

The role of calendars may be growing more important when managing patients with nAMD and DME. How many weeks can patients go between injections with newer anti-VEGF agents versus older options? How short of an injection interval can patients tolerate before it becomes too much of a burden? In this podcast, Murtaza Adam, MD; Laxmi Devisetty, MD, Hong-Uyen Hua, MD; and Sherrol Reynolds, OD; share insights into determining appropriate treatment regimens with these therapies and supporting patient adherence.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

We stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations

XLRP often leads to blindness by middle age with no treatment options currently available

The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR